Curated Wealth Partners LLC Decreases Stock Holdings in Abbott Laboratories $ABT

Curated Wealth Partners LLC trimmed its position in shares of Abbott Laboratories (NYSE:ABT) by 4.2% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 13,327 shares of the healthcare product maker’s stock after selling 587 shares during the quarter. Abbott Laboratories comprises about 0.2% of Curated Wealth Partners LLC’s investment portfolio, making the stock its 28th largest holding. Curated Wealth Partners LLC’s holdings in Abbott Laboratories were worth $1,813,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of ABT. Hughes Financial Services LLC purchased a new stake in shares of Abbott Laboratories during the 1st quarter valued at $27,000. Abound Financial LLC purchased a new stake in Abbott Laboratories in the first quarter valued at about $28,000. Elequin Capital LP purchased a new position in shares of Abbott Laboratories in the 1st quarter valued at approximately $30,000. JCIC Asset Management Inc. purchased a new position in shares of Abbott Laboratories in the 1st quarter valued at approximately $32,000. Finally, Vision Financial Markets LLC purchased a new position in shares of Abbott Laboratories in the 1st quarter valued at approximately $33,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CFO Philip P. Boudreau sold 5,550 shares of the business’s stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the sale, the chief financial officer owned 51,003 shares of the company’s stock, valued at $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Up 1.4%

ABT opened at $133.17 on Wednesday. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The company has a fifty day moving average of $132.62 and a two-hundred day moving average of $131.61. The stock has a market capitalization of $231.77 billion, a price-to-earnings ratio of 16.69, a PEG ratio of 2.49 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. During the same quarter in the previous year, the business earned $1.14 EPS. Abbott Laboratories’s revenue for the quarter was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be issued a $0.59 dividend. This represents a $2.36 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories’s payout ratio is presently 29.57%.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ABT shares. Mizuho raised their price target on shares of Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday. Morgan Stanley raised their price objective on Abbott Laboratories from $127.00 to $137.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Wells Fargo & Company dropped their target price on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating on the stock in a research report on Friday, July 18th. Benchmark began coverage on shares of Abbott Laboratories in a research report on Friday, October 10th. They set a “buy” rating and a $145.00 price target for the company. Finally, The Goldman Sachs Group raised their price target on shares of Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $146.17.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.